{"url_path":"/sec/jsprw/8-k/2026-05-14/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-056596-index.html","accession_number":"0001213900-26-056596","cik":"0001788028","ticker":"JSPR","issuer_name":"Jasper Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-056596-index.html","primary_entity_key":"0001788028","primary_entity_name":"Jasper Therapeutics, Inc."},"word_count":347,"has_tables":true,"body_markdown":"false\n0001788028\n\n0001788028\n\n2026-05-14\n2026-05-14\n\n0001788028\n\nJSPR:VotingCommonStockParValue0.0001PerShareMember\n\n2026-05-14\n2026-05-14\n\n0001788028\n\nJSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member\n\n2026-05-14\n2026-05-14\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n \n\n****\n\n** **\n\n**FORM 8-K**\n\n** **\n\n****\n\n \n\n** **\n\n**CURRENT REPORT\nPURSUANT TO SECTION 13 OR 15(d) OF THE\nSECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\n**Date of Report (Date of earliest event reported):\nMay 14, 2026**\n\n** **\n\n****\n\n \n\n** **\n\n**JASPER THERAPEUTICS, INC.**\n\n**(Exact Name\nof Registrant as Specified in its Charter)**\n\n** **\n\n****\n\n \n\n** **\n\n** **\n\n**Delaware**\n\n \n**001-39138**\n \n**84-2984849**\n\n**(State or Other Jurisdiction\nof Incorporation)**\n \n**(Commission\nFile Number)**\n \n**(IRS Employer**\n\n**Identification No.)**\n\n** **\n\n**2200 Bridge Pkwy Suite #102\nRedwood City, California 94065**\n\n**(Address of Principal Executive Offices) (Zip\nCode)**\n\n** **\n\n**(650) 549-1400**\n\n**Registrant’s telephone number, including\narea code**\n\n** **\n\n**N/A**\n\n**(Former\nName, or Former Address, if Changed Since Last Report)**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Exchange Act:\n\n \n\n**(Title\nof each class)**\n \n**(Trading\nSymbol)**\n \n**(Name\nof exchange on which registered)**\n\n**Voting Common Stock, par value $0.0001 per share**\n \n**JSPR**\n \n**The Nasdaq Stock Market LLC**\n\n**Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00**\n \n**JSPRW**\n \n**The Nasdaq Stock Market LLC**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐"}